Ascom Myco 3 smartphone approved for the Target Platform for Epic Rover

May 14, 2019

The Ascom Myco 3 smartphone made a significant step forward. It has been listed on the Target Platform for the healthcare application Epic Rover.

The app gives clinical users of Epic's Electronic Health Records access to tools for clinical review, medication administration, specimen collection, and other clinical documentation workflows right from their mobile devices.

The Ascom Myco 3 smartphone works together with Ascom and third-party software and apps to put context-rich information from multiple sources into the hands of highly mobile clinicians. Designed for clinical and other demanding environments, the Ascom Myco 3 combines a robust yet ergonomic form with advanced integration capabilities and enterprise-grade security features.

Francis Schmeer, Chief Sales and Marketing Officer of Ascom, says: "This is yet another exciting step forward for the Ascom Myco 3 smartphone and the whole company. With this, our groundbreaking smartphone Ascom Myco 3 gains interoperability for clinicians. It clearly shows how Ascom's strategic approach in pushing software solutions for healthcare is bearing fruit."

Epic and Rover are registered trademarks of Epic Systems Corporation.

This document does not constitute an offer or solicitation to subscribe for, purchase or sell any securities. This document is not being issued in the United States of America or the United Kingdom and should not be distributed in any jurisdiction in a manner where such distribution would not comply with regulatory requirements. In particular, this document may not be distributed into the United States, to United States persons or to publications with a general circulation in the United States. In addition, the securities of Ascom have not been and will not be registered in any jurisdiction outside Switzerland. The securities of Ascom may not be offered, sold or delivered and no solicitation to purchase such securities may be made within the United States or to U.S. persons absent an applicable exemption from the registration requirements of the United States securities laws or within any other jurisdiction and in a manner where such offer, sale, delivery or solicitation might not be in compliance with regulatory requirements (including the United Kingdom).